Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "Rs-1"

270 News Found

Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Lyka Labs  Q2FY22 consolidated PAT at Rs. 28.43Cr
News | November 01, 2021

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021


Sanofi India PAT at Rs. 529.8 cr in Q3CY21
News | October 27, 2021

Sanofi India PAT at Rs. 529.8 cr in Q3CY21

The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021


NPPA fixes ceiling price for anti-diabetic generic medicines
Policy | October 26, 2021

NPPA fixes ceiling price for anti-diabetic generic medicines

A total of 12 generic medicines have been included in the list


India ramps up medical education with substantial investments
Policy | October 25, 2021

India ramps up medical education with substantial investments

A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014


Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
News | October 25, 2021

Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22

The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
News | October 25, 2021

Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22
News | October 22, 2021

Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22

The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment


Domestic growth to the fore as US weakness persists: ICICI Direct
News | October 19, 2021

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report